Atea Pharmaceuticals, Inc.
AVIR
NASDAQ·Healthcare·Biotechnology·Mkt cap $466.6M
$5.83
▲ +0.17%
P/E
-2.80
Mkt Cap
$466.6M
52-Wk Range
$2.78–$6.45
52-Week Range
$2.78 - $6.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 79.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Diversified pipeline targeting multiple high-prevalence viral infections with significant market potential
- Strategic partnership with Merck & Co. providing development expertise and commercialization capabilities
- Proprietary nucleoside and NS5A inhibitor technology platforms enabling pan-genotypic antiviral solutions
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Advancement of AT-527 through Phase II trials for COVID-19 treatment and potential market approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+35.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AVIR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$0.41 vs -$0.56 consensus (+26.1% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+26.1%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AVIR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related